ALLENDALE, N.J., March 24, 2015 /PRNewswire/ — Stryker Corporation’s Spine and Trauma & Extremities Divisions will be launching BIO4™, the next generation viable bone matrix at booth #443 during the American Academy of Orthopaedic Surgeons Annual Meeting in Las Vegas, NV from March 24-28th.
From the creators of the original allograft cellular bone matrix, Osiris Therapeutics, Inc., comes the next generation, BIO4, a viable bone matrix containing endogenous bone forming cells including mesenchymal stem cells, osteoprogenitor cells, osteoblasts, osteoinductive and angiogenic growth factors. BIO4 possesses all four characteristics involved in bone repair and regeneration: osteoconductive, osteoinductive, osteogenic and angiogenic.1, 2 It is a safe alternative to bone autograft that minimizes the potential for harvest site co-morbidities3.
“With the introduction of BIO4, Stryker now plays in the growing $199M4 Cellular Allograft Market,” said Spencer Stiles, President,Stryker Spine. “Stryker offers one of the most comprehensive biologics portfolios on the market featuring the #1 selling synthetic bone graft5, Vitoss, and the next generation viable bone matrix, BIO4.” 
“BIO4 is a new therapeutic alternative to autograft for Foot and Ankle surgery, which avoids secondary surgical sites necessary to harvest autograft tissue,” said Tom Popeck, Vice President and General Manager, Stryker Foot and Ankle. “Unlike many other alternatives to autograft, BIO4 possesses the four characteristics that are important for bone regeneration in a wide range of procedures. We are excited to enter into this new opportunity.”